Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Christian Felipe RuizDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0003-1470-8061
Xiangyu GeYale Cancer Biology Institute, Yale University, West Haven, Connecticut.ORCID 0009-0006-2657-0775
Rylee McDonnellDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0009-0003-5568-3910
Sherry S AgabitiDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-8151-3374
Daniel C McQuaidDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2880-3062
Andy TangDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0009-0003-1095-2072
Meera KharwaDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0009-0000-2163-131X
Jennifer GoodellDepartment of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-8738-8973
Rocío Del M Saavedra-PeñaDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut.ORCID 0000-0003-3332-3597
Allison WingDepartment of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, Connecticut.ORCID 0009-0001-8993-199X
Guangtao LiDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-5460-1288
Natasha Pinto MediciDepartment of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-9848-0943
Marie E RobertDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-6385-4578
Rohan R VarshneyDepartment of Biochemistry and Physiology and Harold Hamm Diabetes Center, University of Oklahoma University Health Sciences, Oklahoma City, Oklahoma.ORCID 0000-0002-8580-3675
Michael C RudolphDepartment of Biochemistry and Physiology and Harold Hamm Diabetes Center, University of Oklahoma University Health Sciences, Oklahoma City, Oklahoma.ORCID 0000-0002-6147-212X
Fred S GorelickM.D.-Ph.D. Program, Yale University, New Haven, Connecticut.ORCID 0000-0001-8293-6803
John WysolmerskiYale Cancer Center and Smilow Cancer Hospital, Yale University, New Haven, Connecticut.ORCID 0000-0003-3037-1008
Daniel CanalsDepartment of Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0002-9293-5123
John D HaleyDepartment of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York.ORCID 0000-0003-2652-4841
Matthew S RodehefferTranslational Molecular Medicine, Pharmacology, and Physiology Program, Yale University, New Haven, Connecticut.ORCID 0000-0001-8893-2125
Mandar Deepak MuzumdarDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-7424-7223
Funding
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI Eric P. Winer · 1985 to 2026
$85.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9M
Sphingolipids in Cancer Therapy and AngiogenesisP01CA097132 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI Fabiola Velazquez · 2003 to 2026
$30.8M
Cellular & molecular mechanisms of white adipose tissue mass regulationR01DK090489 · NIDDK · YALE UNIVERSITY · PI RODEHEFFER, MATTHEW S · 2011 to 2020
$3.8M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
Dietary fatty acids drive pancreatic cancer developmentR01CA276108 · NCI · YALE UNIVERSITY · PI Mandar Deepak Muzumdar · 2023 to 2026
$2.6M
Defining tumor cell and host adaptations in cancer progressionDP2CA248136 · NCI · YALE UNIVERSITY · PI MUZUMDAR, MANDAR DEEPAK · 2019 to 2019
$2.5M
The role of mitochondrial dynamics in diet-influenced regulation of food intake and adiposityR01DK126447 · NIDDK · YALE UNIVERSITY · PI HORVATH, TAMAS L, RODEHEFFER, MATTHEW S · 2021 to 2024
$2.3M
American Association for Cancer Research (AACR) 2021 Fellowship to Further Diversity, Equity, and Inclusion in Immuno-oncology ResearchBLRD VA I01 BX003250Damon Runyon Cancer Research Foundation (DRCRF) 66-21Ford Foundation (FF) Predoctoral FellowshipLustgarten Foundation (Lustgarten) Innovation and Collaboration GrantNational Cancer Institute (NCI) P30-CA016359National Cancer Institute (NCI) R01-CA276108National Cancer Institute (NCI) R01-CA276108-03S1National Cancer Institute (NCI) T32-CA193200National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01-DK090489National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01-DK126447National Institute of General Medical Sciences (NIGMS) 5T32-GM007205National Science Foundation Graduate Research Fellowship Program (GRFP)NCI NIH HHS DP2 CA248136NCI NIH HHS P01 CA097132NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA276108NCI NIH HHS T32 CA193200NIDDK NIH HHS R01 DK090489NIDDK NIH HHS R01 DK126447NIGMS NIH HHS T32 GM007205NIH Office of the Director (OD) DP2-CA248136U.S. Department of Veterans Affairs (VA) BX003250Women's Health Research at Yale, Yale School of Medicine (WHRY) Naratil Pioneer AwardYale Cancer Center Team Challenge AwardYale University (Yale) James Hudson Brown-Alexander B. Coxe FellowshipYale University (Yale) Lo Fellowship for Excellence in Stem Cell ResearchYale University (Yale) STARS
6 · The paper itself
Abstract
High-fat diet (HFD) intake has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), a lethal and therapy-resistant cancer. However, whether and how specific dietary fats drive cancer development remains unresolved. Leveraging an oncogenic Kras-driven mouse model that closely mimics human PDAC progression, we screened a dozen isocaloric HFDs differing solely in fat source and representing the diversity of human fat consumption. Unexpectedly, diets rich in oleic acid-a monounsaturated fatty acid (MUFA) typically associated with good health-markedly enhanced tumorigenesis. Conversely, diets high in polyunsaturated fatty acids (PUFA) suppressed tumor progression. Relative dietary fatty acid saturation levels (PUFA/MUFA) governed pancreatic membrane phospholipid composition, lipid peroxidation, and ferroptosis sensitivity in mice, concordant with circulating PUFA/MUFA levels being linked to altered PDAC risk in humans. These findings directly implicate dietary unsaturated fatty acids in controlling ferroptosis susceptibility and tumorigenesis, supporting potential "precision nutrition" strategies for PDAC prevention. SIGNIFICANCE: This study reveals that dietary unsaturated fatty acids divergently influence pancreatic cancer progression by incorporating into tissue phospholipids to modulate ferroptosis sensitivity. Dietary MUFAs promote tumorigenesis, whereas PUFAs confer protection. These findings suggest that alterations in dietary fat intake could affect cancer risk. See related commentary by Jeong and Lien, p. 1961.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Diet-Induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas. · full record | OpenQuestion